Compare · DRAD vs TMDX
DRAD vs TMDX
Side-by-side comparison of Digirad Corporation (DRAD) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRAD and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX carries a market cap of $3.20B.
- TMDX has hit the wire 8 times in the past 4 weeks while DRAD has been quiet.
- TMDX has more recent analyst coverage (20 ratings vs 0 for DRAD).
- Company
- Digirad Corporation
- TransMedics Group Inc.
- Price
- -
- -
- Market cap
- -
- $3.20B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2004
- 2019
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 20
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest DRAD
- SEC Form 8 filed
- Digirad Corporation to Present at Investor Conferences in November
- Digirad Corporation Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2020
- Digirad Corporation to Release Third Quarter 2020 Financial Results on November 13
- Digirad Corporation to Sell DMS Health for $18.75 Million
Latest TMDX
- Director Tobin James R sold $385,464 worth of shares (4,059 units at $94.97), decreasing direct ownership by 58% to 2,922 units (SEC Form 4)
- SEC Form 144 filed by TransMedics Group Inc.
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Third Quarter 2026 Financial Results
- Officer Araujo Fernando N. was granted 22,969 shares (SEC Form 4)
- TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- TransMedics to Present at Upcoming Investor Conferences
- TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026
- Barclays initiated coverage on TransMedics Group with a new price target